3478
N. Bharti et al. / Bioorg. Med. Chem. Lett. 12 (2002) 3475–3478
Table 2. In vitro activities of thiosemicarbazones against E. histoly-
tica (HK-9), T. vaginalis (tv-43) and G. lamblia (IMSS-0989)
17. Tedlaouti, F.; Gasquest, M.; Delmas, F.; Majester, B.;
Timon-David, P.; Madadi, N. E.; Vanelle, P.; Maldonado, J.
Farmaco 1991, 46, 1195.
18. Delmas, F.; Gasquet, M.; Timon-David, P.; Madadi, N.;
Vanelle, P.; Vaille, A.; Maldonado, J. Eur. J. Med. Chem.
1993, 28, 23.
CompdAntiamoebic
IC50 (mM)
Antitrichomonal
IC50 (mM)
Anitailgiard
IC50 (mM)
19. O’Sullivan, D. G.; Sadler, P. W.; Webley, C. Chemother-
apia 1963, 7, 17.
1
2
3
4
5
6
7
8
15.38ꢂ1.94
9.60ꢂ1.07
12.17ꢂ0.98
13.50ꢂ2.15
10.10ꢂ1.46
6.40ꢂ0.91
11.63ꢂ2.05
8.30ꢂ1.26
2.86ꢂ0.45
2.41ꢂ0.51
1.71ꢂ0.38
2.10ꢂ0.33
21.03ꢂ3.16
5.94ꢂ0.89
1.49ꢂ0.31
6.31ꢂ1.14
6.01ꢂ0.85
4.06ꢂ0.65
4.44ꢂ3.07
18.30ꢂ3.07
3.97ꢂ0.59
10.70ꢂ1.34
8.78ꢂ1.16
1.92ꢂ0.28
57.26ꢂ7.28
26.19ꢂ3.72
17.19ꢂ2.63
33.33ꢂ4.87
8.03ꢂ1.34
8.20ꢂ1.19
12.01ꢂ1.86
11.72ꢂ1.42
32.99ꢂ4.07
13.90ꢂ2.15
8.47ꢂ1.24
1.16ꢂ0.21
20. 1. lmax/cmꢀ1: 24,752, 35,842, 40,816, 48,780; nmax/cmꢀ1
:
1
3322 (NH), 1556 (C¼N), 1135 (C–N), 1033 (C¼S); H NMR
((CD3)2SO)/ppm: 8.04 (1H, s, –CH¼N), 11.40 (1H, s, –NH),
8.25 (1H, t, –NH), 4.20 (4H, m, –CH2), 2.21 (3H, t, –CH3),
7.03–8.12 (2H, m, aryl). 2. lmax/cmꢀ1: 25,000, 36,101, 40,322,
48,309; nmax/cmꢀ1: 3428 (NH), 1600 (C¼N), 1093 (C–N), 1035
(C¼S); 1H NMR ((CD3)2SO)/ppm: 8.06 (1H, s, –CH¼N),
10.62 (1H, s, –NH), 8.47(1H, d, –NH), 2.95 (6H, d, –CH3),
6.93–7.82 (2H, m, aryl). 3. lmax/cmꢀ1: 24,752, 36,496, 38,610,
48,309; nmax/cmꢀ1: 3434 (NH), 1590 (C¼N), 1095 (C–N), 1040
(C¼S); 1H NMR ((CD3)2SO)/ppm: 8.39 (1H, s, –CH¼N),
10.96 (1H, s, –NH), 8.51 (1H, t, –NH), 4.12 (6H, m, –CH2),
9
10
11
MNZ
2.19 (3H, t, –CH3), 7.06–8.01 (2H, m, aryl). 4. lmax/cmꢀ1
:
compound 3 and 11 towards mammalian cells are
currently underway, as well as in vivo studies on
trichomonocidal and amoebicidal activity.
25,470, 36,232, 38,461, 48,544; nmax/cmꢀ1: 3460 (NH), 1595
1
(C¼N), 1106 (C–N), 1052 (C¼S), H NMR ((CD3)2SO)/ppm:
8.09 (1H, s, –CH¼N), 11.23 (1H, s, –NH), 8.21(1H, d, –NH),
4.46 (2H, m, –CH2), 1.99 (6H, m, –CH3), 7.23–8.04 (2H, m,
aryl). 5. lmax/cmꢀ1: 24,752, 36,496, 38,712, 45,045; IR: nmax
/
Acknowledgements
1
cmꢀ1: 3384 (NH), 1585 (C¼N), 1106 (C–N), 1036 (C¼S); H
NMR ((CD3)2SO)/ppm: 8.39 (1H, s, –CH¼N), 10.02 (1H, s, –
NH), 2.53 (6H, m, –CH3), 4.23 (4H, m, –CH2), 7.40–8.12 (2H,
Neelam Bharti acknowledges a Senior Research Fel-
lowship from Council of Scientific andInudstrial
Research, New Delhi, India.
m, aryl). 6. lmax/cmꢀ1: 24,630, 35,211, 47,847; nmax/cmꢀ1
:
1
3494 (NH), 1492 (C¼N), 1121 (C–N), 1050 (C¼S); H NMR
((CD3)2SO)/ppm: 8.29 (1H, s, –CH¼N), 10.43 (1H, s, –NH),
4.30 (8H, m, –CH2), 2.19 (6H, t, –CH3), 7.01–7.92 (2H, m,
aryl). 7. lmax/cmꢀ1: 24,938, 37,879, 48,309; nmax/cmꢀ1: 3422
(NH), 1630 (C¼N), 1117 (C–N), 1037 (C¼S); 1H NMR
((CD3)2SO)/ppm: 8.45 (1H, s, –CH¼N), 9.98 (1H, s, –NH),
3.98 (4H, m, –CH2), 1.99 (12H, m, –CH3), 6.89–7.53 (2H, m,
aryl). 8. lmax/cmꢀ1: 24,630, 34,965, 48,312; nmax/cmꢀ1: 3469
(NH), 1570 (C¼N), 1139 (C–N), 1087 (C¼S); 1H NMR
((CD3)2SO)/ppm: 8.34 (1H, s, –CH¼N), 11.14 (1H, s, –NH),
4.53 (10H, m, –CH2), 2.56 (3H, s, –CH3), 7.23–8.04 (2H, m,
References and Notes
1. WHO epidemiol. Record 1997, 14, 4.
2. Craun, G. F. In Giardiasis and Giardiasis: Biology, Patho-
gensis, and Epidemiology; Erlandsen, S. L.; Meyer, E. A., Eds.,
Plenum: New York, 1996; p 243.
3. Kramer, M. H.; Herwaldet, B. L.; Craun, G. F.; Calderon,
R. L.; Juranek, D. D. CDC Surveillance Summaries; April 12,
Morb. Mortal. Weekly Rep. 1996; p 45,1.
4. Townson, S. M.; Boreham, P. F. L.; Upcroft, P.; Upcroft,
J. A. Acta Trop. 1994, 56, 173.
5. Narcisi, E. M.; Secor, W. E. Antimicrob. Agents Chemother.
1996, 40, 1121.
6. Upcroft, J. A.; Upcroft, P. Parasitol. Today 1993, 9, 187.
7. Knight, R. J. Antimicrob. Chemother. 1980, 6, 577.
8. Khaw, M.; Panosian, C. B. Clinic. Microbiol. Rev. 1995,
427.
9. Voogd, C. E.; Vander Stel, J. J.; Jacobs, J.J.J.A.A. Mutat.
Res. 1974, 31, 149.
10. Martindale, the Extra Pharmacopia, Reynolds, G. E. F.,
Ed.; 28th ed.; Pharmaceutical: London, 1982; p 968.
11. Scovill, J. P.; Klayman, D. L.; Lambrose, C.; Childs,
G. E.; Notsch, J. D. J. Med. Chem. 1984, 27, 87.
12. Loiseau, P. M.; Nguyen, D. X. Trop. Med. Int. Health
1996, 1, 379.
aryl). 9.lmax/cmꢀ1: 24,635, 35,461, 40,123, 49,020; IR: nmax
/
cmꢀ1: 3456 (NH), 1664 (C¼N), 1120 (C–N), 1039 (C¼S); H
NMR ((CD3)2SO)/ppm: 8.44 (1H, s, –CH¼N), 10.69 (1H, s, –
NH), 8.76 (1H, d, –NH), 4.23 (8H, m, –CH2), 7.07–7.87 (2H,
m, aryl). 10. lmax/cmꢀ1: 24,755, 35,714, 40,112, 48,913; IR:
1
n
max/cmꢀ1: 3472 (NH), 1532 (C¼N), 1108 (C–N), 1034 (C¼S);
1H NMR ((CD3)2SO)/ppm: 8.21 (1H, s, –CH¼N), 10.05 (1H,
s, –NH), 8.65 (1H, d, –NH), 4.53 (10H, m, –CH2), 6.97–7.54
(2H, m, aryl). 11. lmax/cmꢀ1: 24,630, 36,101, 38,315, 48,780;
n
max/cmꢀ1: 3402 (NH), 1583 (C¼N), 1090 (C–N), 1035 (C¼S);
1H NMR ((CD3)2SO)/ppm: 8.23 (1H, s, –CH¼N), 9.81 (1H, s,
–NH), 4.39 (12H, m, –CH2), 7.13–7.79 (2H, m, aryl).
21. Diamond, L. S.; Harlow, D. R.; Cunnick, C. C. Trans. R.
Soc. Trop. Med. Hyg. 1978, 72, 431.
22. Said-Fernandez, S.; Vargas-Villareal, J.; Castro-Garza, J.;
Mata-Cardenas, B. D.; Navarro-Marmolejo, L.; Lozano-
Garza, G.; Martinez-Rodriguez, H. Trans. Roy. Soc. Trop.
Med. Hyg. 1988, 82, 249.
23. Wright, C. W.; O’Neill, M. J.; Phillipson, J. D.; Warhurst,
D. C. Antimicrob. Agents Chemother. 1988, 32, 1725.
24. Gillin, F. D.; Reiner, D. S.; Suffness, M. Antimicrob.
Agents Chemother. 1982, 22, 342.
13. Shipman, C.; Smith, S. H.; Drach, J. C.; Klayman, D. L.
Antiviral Res. 1986, 6, 197.
14. Cerecetto, H.; DiMaio, R.; Ibarruri, G.; Seoane, G.;
Denicola, A.; Peluffo, G.; Quijano, C.; Paulino, M. IL Farm-
aco 1998, 53, 89.
25. Neal, R. A. Parasitol. 1983, 86, 175.
26. Gault, M. J.; Reiner, D. S.; Gillin, F. D. Trans. Roy. Soc.
Trop. Med. Hyg. 1985, 79, 60.
15. Maldonado, J.; Ghemri, H.; Vanelle, P.; Crozet, M.;
Timon-David, P.; Julien, M. J.; Gasquet, M. Eur. J. Med.
Chem. 1986, 21, 521.
27. Dobek, A. S.; Klayman, D. L.; Dickson, E. T., Jr.; Scvill,
J. P.; Tramont, E. C. Antimicrob. Agents Chemother. 1980, 28,
27.
16. Tedlaouti, F.; Gasquet, M.; Delmas, F.; Timon-David, P.;
Madadi, N. E.; Vanelle, P.; Maldonado, J. J. Pharm. Belg.
1990, 45, 306.